Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 206 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Jazz Pharmaceuticals Clear all
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

NCT01887301
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Sativex
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

NCT05391724
View directory record Official record
Conditions
Hepatic Impairment
Interventions
CMX001
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 3, 2026, 5:54 PM EDT
Not yet recruiting Phase 4 Interventional

A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

NCT07728097
View directory record Official record
Conditions
Lennox-Gastaut Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 3, 2026, 5:54 PM EDT
Recruiting Phase 2 Interventional

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

NCT07282587
View directory record Official record
Conditions
Advanced Pheochromocytoma and Paraganglioma, PCPG
Interventions
ONC206, ONC206: Dose 1, ONC206: Dose 2
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT03878199
View directory record Official record
Conditions
Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Columbus, Ohio • Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Recruiting Phase 1 Interventional

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

NCT05542407
View directory record Official record
Conditions
Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma, Serous Adenocarcinoma of Endometrium (Diagnosis), Clear Cell Endometrial Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Interventions
Atezolizumab, ONC201
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

NCT02953548
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 3, 2026, 5:54 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT03848832
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

NCT04447846
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Cannabidiol
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
3 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 3, 2026, 5:54 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 3, 2026, 5:54 PM EDT
Recruiting Phase 1 Interventional

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

NCT06108050
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP898, Pembrolizumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Encinitas, California • Fresno, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Enhancing Slow Wave Sleep With Sodium Oxybate

NCT00506974
View directory record Official record
Conditions
Sleep
Interventions
sodium oxybate
Drug
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 3, 2026, 5:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Lurbinectedin in FET-Fused Tumors

NCT05918640
View directory record Official record
Conditions
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Interventions
Lurbinectedin
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Los Angeles, California • Iowa City, Iowa • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

NCT00361842
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.

NCT02325011
View directory record Official record
Conditions
Healthy Subjects
Interventions
Sativex® (Treatment A), Sativex® and fluconazole concomitantly (Treatment B)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

NCT01241344
View directory record Official record
Conditions
Adenovirus Disease
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
3 Months to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

NCT02954887
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 3, 2026, 5:54 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

NCT06961266
View directory record Official record
Conditions
Narcolepsy
Interventions
JZP441, Matching Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Recruiting Phase 2 Interventional

Combination Therapy for the Treatment of Diffuse Midline Gliomas

NCT05009992
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions
ONC201, Radiation Therapy, Paxalisib, DNX-2401
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

NCT03030599
View directory record Official record
Conditions
Narcolepsy With Cataplexy
Interventions
JZP-258, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
12
States / cities
Orange, California • Stanford, California • Boulder, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 3, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)

NCT00931164
View directory record Official record
Conditions
Alternating Hemiplegia of Childhood
Interventions
Sodium Oxybate
Drug
Lead sponsor
University of Utah
Other
Eligibility
6 Months to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 3, 2026, 5:54 PM EDT